Physician profile
Brian J Larson
NPI 1861498370
$2,819.28
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $294 · 2021: $31.75 · 2022: $526 · 2023: $544 · 2024: $99.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $442.31 | 2019-2023 | Provenge |
| Janssen Biotech, INC. | $351.55 | 2019-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $286.50 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.34 | 2019-2023 | |
| Pfizer INC. | $185.50 | 2019-2023 | |
| Genzyme Corporation | $134.38 | 2019-2023 | |
| Astellas Pharma US INC | $121.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $114.36 | 2019-2022 | |
| Allergan, INC. | $105.75 | 2020 | |
| Tempus Ai, INC | $99.94 | 2024 | |
| Amgen INC. | $89.80 | 2019-2020 | |
| Exelixis INC. | $75.52 | 2019-2023 | Cabometyx |
| Varian Medical Systems, INC. | $72.88 | 2019 | |
| Sun Pharmaceutical Industries INC. | $72.32 | 2019-2023 | Yonsa |
| Astrazeneca Pharmaceuticals LP | $61.14 | 2023 | Lynparza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $56.39 | 2019 | |
| Eisai INC. | $47.27 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $40.75 | 2022-2023 | Prolaris |
| Medtronic, INC. | $31.75 | 2021 | |
| Merck Sharp & Dohme LLC | $28.73 | 2019-2022 | |
| Tolmar, INC. | $27.37 | 2023 | |
| Axonics, INC. | $26.31 | 2022-2023 | Axonics |
| Blue Earth Diagnostics | $21.64 | 2019 | |
| Mylan Institutional INC. | $19.08 | 2019 | |
| Emd Serono, INC. | $17.67 | 2023 | Bavencio |
| Daiichi Sankyo INC. | $16.32 | 2022 | |
| Angiodynamics, INC. | $16.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.03 | 2019 | |
| Myovant Sciences INC. | $15.02 | 2022 | |
| Seagen INC. | $15.02 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.